TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company
Transcenta, biologics, antibody
09 Jan, 2020
Transcenta tops off $100M series B+
Transcenta Holding Ltd. raised $20 million in a second tranche of its series B+, bringing the total amount raised in the round to $100 million. CR-CP Life Science Fund and Fortune Capital led the round, which saw participation by new investors Epiphron Capital, CCT China Merchant Buyout Fund, China Equity Group and existing investors Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners, Sequoia Capital China and ARCH Venture Partners.